


Spotlight on Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma is the eighth-most common cancer type in the U.S., with an estimated 80,350 new cases diagnosed in 2025.

Because of game-changing research, the age-adjusted death rates of non-Hodgkin lymphoma have been falling on average by about 2% per year from 2014 to 2023. The five-year relative survival rate is 74%.

Non-Hodgkin lymphoma is most common among older, white men.



Our Impact on Non-Hodgkin Lymphoma Research

We've funded

21 grants totaling \$7.43 million.

V Foundation funded researchers, over their careers, have:

Received

397 grants and over \$6.8 billion in funding.

Produced

over 7,100 publications.

Worked on

94 clinical trials.

V Foundation Funded Researchers – Proven Positive Impact

- **Ash Alizadeh, M.D., Ph.D.**, a 2014 V Scholar at Stanford University, develops tools that analyze DNA found in bodily fluids that could be used for screening and monitoring large B-cell lymphoma (LBCL), a type of non-Hodgkin's lymphoma.
- This type of "liquid biopsy" has the potential to be a minimally invasive way to assess patient risk and monitor tumors over time.
- In an exciting publication, Dr. Alizadeh used a new method for analyzing circulating tumor DNA to look for ways to predict outcomes in lymphoma patients receiving CAR-T immunotherapy. Traditionally, many LBCL patients experience disease progression while in treatment.
- They were able to discover multiple categories of genes that are associated with resistance to CAR-T therapy.
- Dr. Alizadeh's findings have the potential to help clinicians predict who will and will not respond to therapy in a non-invasive way, personalizing treatment approaches, and avoiding toxic therapy in patients who are unlikely to respond.



*Alizadeh, M.D., Ph.D.,
2014 V Scholar*